Skip to content

Study · Randomized controlled trial · n = 16 · 2018

6 results

Effects of intranasal oxytocin on satiety signaling in people with schizophrenia.

Warren KR, Wehring HJ, Liu F, McMahon RP, Chen S, Chester C, Kelly DL

Physiology & behavior7 Mar 2018Cited by 6 (Europe PMC)

PMID29524451 (opens in a new tab)DOI10.1016/j.physbeh.2018.03.008 (opens in a new tab)PepBankPUB-29524451
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with schizophrenia, intranasal oxytocin did not change self-reported satiety compared with placebo.

    In plain wordsIn people with schizophrenia, oxytocin nasal spray did not change self-reported fullness compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSelf-reported satiety
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences between the groups on self-reported satiety or test meal consumption, insulin or glucose levels, or sensory measures.
    1 context sentence
    Summary · context
    This two-day, within-subjects, challenge study involved the examination of satiety after administration of 24 IU oxytocin (intranasal) vs. placebo in participants with a DSM-IV diagnosis of schizophrenia (N = 16).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with schizophrenia, intranasal oxytocin did not change test meal consumption compared with placebo.

    In plain wordsIn people with schizophrenia, oxytocin nasal spray did not change how much they ate at a test meal compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeTest meal consumption
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences between the groups on self-reported satiety or test meal consumption, insulin or glucose levels, or sensory measures.
    1 context sentence
    Summary · context
    This two-day, within-subjects, challenge study involved the examination of satiety after administration of 24 IU oxytocin (intranasal) vs. placebo in participants with a DSM-IV diagnosis of schizophrenia (N = 16).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In people with schizophrenia, intranasal oxytocin did not change insulin levels compared with placebo.

    In plain wordsIn people with schizophrenia, oxytocin nasal spray did not change insulin levels compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeInsulin levels
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences between the groups on self-reported satiety or test meal consumption, insulin or glucose levels, or sensory measures.
    1 context sentence
    Summary · context
    This two-day, within-subjects, challenge study involved the examination of satiety after administration of 24 IU oxytocin (intranasal) vs. placebo in participants with a DSM-IV diagnosis of schizophrenia (N = 16).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In people with schizophrenia, intranasal oxytocin did not change glucose levels compared with placebo.

    In plain wordsIn people with schizophrenia, oxytocin nasal spray did not change blood glucose compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeGlucose levels
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences between the groups on self-reported satiety or test meal consumption, insulin or glucose levels, or sensory measures.
    1 context sentence
    Summary · context
    This two-day, within-subjects, challenge study involved the examination of satiety after administration of 24 IU oxytocin (intranasal) vs. placebo in participants with a DSM-IV diagnosis of schizophrenia (N = 16).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In people with schizophrenia, intranasal oxytocin did not change sensory (taste and smell) measures compared with placebo.

    In plain wordsIn people with schizophrenia, oxytocin nasal spray did not change taste or smell measures compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeTaste and smell measures
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Self reported satiety along with a preload-test meal paradigm were utilized as well as related laboratory measures (insulin, glucose, and leptin), and measures of taste and smell. There were no statistically significant differences between the groups on self-reported satiety or test meal consumption…
    1 context sentence
    Summary · context
    This two-day, within-subjects, challenge study involved the examination of satiety after administration of 24 IU oxytocin (intranasal) vs. placebo in participants with a DSM-IV diagnosis of schizophrenia (N = 16).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In people with schizophrenia, leptin was lower in the oxytocin group than in the placebo group after administration, with no time effect and no treatment by time interaction.

    In plain wordsIn people with schizophrenia, leptin was lower after oxytocin nasal spray than after placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseLeptin level
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Measurements

    Treatment effect p value
    0.025
    leptin

    Source sentences

    Summary
    A significant treatment difference was found (F = 5.22, df = 1,97.6, p = 0.025), with a decrease in leptin in the oxytocin group post-administration, but no time effect (F = 1.67, df = 6,95.1, p = 0.180) or treatment by time interaction (F = 1.36. df = 3,4.16, p = 0.261).
    1 context sentence
    Summary · context
    This two-day, within-subjects, challenge study involved the examination of satiety after administration of 24 IU oxytocin (intranasal) vs. placebo in participants with a DSM-IV diagnosis of schizophrenia (N = 16).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.